

RESOURCES

PEOPLE



InforMax (Rockville, MD) has announced the appointment of **James Bernstein** as president and chief operating officer. Dr. Bernstein has served as a director since InforMax's

inception and was appointed COO and executive vice president of strategic development in 1998.

Christopher G. Clement, formerly senior vice president and chief marketing officer of Ares-Serono Group, has been appointed CEO of EPIcyte Pharmaceutical (San Diego, CA).

Genomics Collaborative (Cambridge, MA) has announced the appointment of **Michael R. Dougherty** as president and COO. Mr. Dougherty has served as chief financial officer at Centocor, and was most recently president and CEO of Magainin Pharmaceuticals.

Timothy J. Henkel has been appointed chief medical officer and executive vice president of Versicor (Fremont, CA). He joins the company from SmithKline Beecham Pharmaceuticals, where he served as vice president of worldwide anti-infective clinical development.

Structural Bioinformatics (San Diego, CA) has announced that **Ian McDonald** has joined the company as vice president of drug discovery. Dr. McDonald was most recently senior director of chemistry at Merck Research Laboratories, which in 1999 acquired SIBIA Neurosciences, where he served as vice president from 1994 and director of chemistry since 1993.

Amgen (Thousand Oaks, CA) has named two executive vice presidents. **Roger M. Perlmutter** will lead Amgen's R&D organization. Dr. Perlmutter was formerly executive vice



president, worldwide basic research and pre-clinical development for Merck Research Laboratories. In addition, **George Morrow** will assume responsibility for worldwide sales and marketing activities. Mr. Morrow was most recently president and CEO, North America for Glaxo Wellcome.

Ribozyme Pharmaceuticals (Boulder, CO) has named **Howard W. Robin** to the newly created position of chief operating officer and president. He is also expected to join the company's board of directors. Most recently, Mr. Robin served as corporate vice president and general manager, therapeutics for Berlex Laboratories, the US subsidiary of Schering

AG. Former president **Ralph E. Christoffersen** will remain as CEO.

Genentech (S. San Francisco, CA) has announced the appointment of **Richard H. Scheller** to senior vice president, research. In addition, he will be a member of Genentech's executive committee and chair of its research review committee. Dr. Scheller currently serves as professor of molecular and cellular physiology and of biological sciences at Stanford University Medical Center, and is an investigator at the Howard Hughes Medical Institute.



NewBiotics (San Diego, CA) has announced that its chief scientific officer and co-founder, **H. Michael Shepard**, has been named president. Previously, Dr. Shepard was CSO and vice president of research at Canji, Inc., and a research scientist at Genentech.

Jackie M. Walling has been appointed vice president of clinical oncology of Axys Pharmaceuticals (S. San Francisco, CA). She joins the company from Tularik, where she was medical director for the past two years. Axys also announced the appointment of **Douglas H. Altschuler** as vice president and general counsel. Previously, he held the same position at Mentor Corp. He succeeds **William J. Newell**, who will continue as senior vice president, corporate and business development.

Lynx Therapeutics (Hayward, CA) has announced the appointments of **Richard Woychik** as chief scientific officer and **William Wong** as vice president, business development. Dr. Woychik joins the company from Pfizer, where he was senior director and head of its molecular genetics research center in Alameda, CA. Dr. Wong was most recently executive vice president of business development at Nexell Therapeutics. Lynx also named **Craig C. Taylor** chairman of its board of directors. He takes over the role from **Sam Eletr**, who is leaving the board and is expected to remain as a consultant to the company. Mr. Taylor has served as a director of Lynx since March 1994.

John L. Zabriskie, a former president and CEO of Pharmacia Upjohn, has been named to the board of directors of Array BioPharma (Boulder, CO). This new appointment brings the total number of board members to nine. Dr. Zabriskie is also a past chairman of the board, CEO, and president of NEN Life Science Products.